Patents
Literature
Hiro is an intelligent assistant for R&D personnel, combined with Patent DNA, to facilitate innovative research.
Hiro

245 results about "Polyhistidine-tag" patented technology

A polyhistidine-tag is an amino acid motif in proteins that typically consists of at least six histidine (His) residues, often at the N- or C-terminus of the protein. It is also known as hexa histidine-tag, 6xHis-tag, His6 tag, by the US trademarked name HIS TAG (US Trademark serial number 74242707), and most commonly as His-Tag. The tag was invented by Roche, although the use of histidines and its vectors are distributed by Qiagen. Various purification kits for histidine-tagged proteins are available from Qiagen, Sigma, Thermo Scientific, GE Healthcare, Macherey-Nagel, Cube Biotech, Clontech, Bio-Rad, and others.

Gene Engineering Recombinant Anti-CEA, Anti-CD3, And Anti-CD28 Single-Chain Tri-Specific Antibody

The invention is related to a recombinant single-chain tri-specific antibody made from anti-Tumor Associated Antigen (TAA) antibody, FC interlinker, anti-CD3 antibody, HSA interlinker and anti-CD28 antibody in turn. Particularly, the invention relates to an anti-CEA, anti-CD3, anti-CD28 recombinant single-chain tri-specific antibody, CEA-scTsAb, which was constructed with three tandem antibody fragments (anti-CEA scFv, anti-CD3 scFv and anti-CD28 single-domain antibody) linked by two interlinkers (FC interlinker, HSA interlinker), and could be appended by C myc tag or histidine tag ((His)6-tag) at the C terminal. It also concerns a method for construction, expression and purification of the antibody. It also offers the encoded DNA sequence of the antibody, expression vectors and host cells for the vectors.
Owner:WANG XIANGBIN +5

Monoclonal antibody blocking enzyme-linked immunosorbent assay (ELISA) kit and method for detecting nonstructural protein (NSP) antibody of foot-and-mouth disease virus (FMDV)

The invention discloses a monoclonal antibody blocking enzyme-linked immunosorbent assay (ELISA) kit and a method for detecting the nonstructural protein (NSP) antibody of a foot-and-mouth disease virus (FMDV) (FMD NSP B-ELISA); the kit comprises ELISA reaction plates, serum diluent, 25 times concentrated detergent, substrate solution, 100* concentrated ELISA detecting antibody, stop buffer, positive control serum and negative control serum; the ELISA reaction plates are two 96-pore high-affinity ELISA reaction plates, firstly 6* groups of amino acid monoclonal antibody or NSP 2C polyclonal antibody, and then FMDV 3ABC or 2C3AB NSP which is expressed by pronucleus and is provided with 6* groups of amino acid labels is captured through the monoclonal antibody or the polyclonal antibody; and compared with other similar kits, the method has higher coincidence rate and higher positive serum detection rate, and is applicable to detecting the serum of cattle, sheep, pigs and other susceptible animals.
Owner:LANZHOU INST OF VETERINARY SCI CHINESE ACAD OF AGRI SCI

Preparation of magnetic silicon dioxide microsphere with metallic ion chelated surface and use thereof

The invention relates to a method for preparing magnetic silicon dioxide microspheres with the surfaces chelated with metal ions; the method of the inventioncomprises the following steps of preparation of the magnetic silicon dioxide microspheres, epoxidation of the magnetic silicon dioxide microspheres, carboxylation of the magnetic silicon dioxide microspheres and chelation technique of metal ions. Compared with the existing preparing method, the method of the invention has the advantages of reasonable design, simple operation and large amount of chelation of metal, etc. The magnetic silicon dioxide microspheres with the surfaces chelated with the metal ions, which are prepared by adopting the method, contain cobalt ions, have stronger bonding force with the modified microspheres so as to lead the cobalt ions to be not easy to leak out, and have higher selectivity and proper bonding strength with histidine on the protein, thus leading the magnetic silicon dioxide microspheres with the surfaces chelated with the metal ions to have high selectivity to hexameric histidine tag protein, and being easy to realize the separation and the purification of the target protein; the magnetic silicon dioxide microspheres with the surfaces chelated with the metal ions, which are prepared by adopting the method, can be used for separating the hexameric histidine tag protein.
Owner:SHAANXI NORMAL UNIV

Purification of vascular endothelial growth factor-B

The present invention provides a method for purifying recombinant peptides, polypeptides or proteins away from truncated or other full-length forms of these molecules. In particular the invention contemplates a method of purifying a vascular endothelial growth factor (VEGF) molecule by subjecting a biological sample containing the molecule to be purified to affinity chromatography under conditions sufficient for the full length molecules to bind and not the truncated or clipped forms. In the preferred embodiment there are two columns, the first is based on affinity for a poly his tag, the second column based on heparin binding affinity. Particularly preferred VEGF molecules are untagged VEGF-B167, hexa-His-tagged VEGF-B167, hexa-His-tagged VEGF-B186 and hexa-His-tagged VEGF-B10-108.
Owner:AMRAD OPERATIONS PTY LTD

Enzyme immobilization method and application

The invention discloses a simple and convenient method for recombinase immobilization. According to the method, the characteristic that a histidine label of recombinant protein and metal ion affinity chromatography resin are combined specifically is utilized, and therefore recombinase is immobilized on the resin, and the immobilized recombinase is prepared. Immobilized carbonyl reductase is used for continuous production of chiral alcohol, and the space time yield is greatly increased.
Owner:CHENGDU INST OF BIOLOGY CHINESE ACAD OF S

Nucleic acid aptamer capable of identifying HCV E1E2 (hepatitis C virus E1E2), nucleic acid aptamer derivatives and screening method and application thereof

The invention discloses a nucleic acid aptamer capable of identifying HCV E1E2 (hepatitis C virus E1E2), which is a DNA fragment having a sequence shown in any one of SEQ ID No.1 to SEQ ID No.5. Derivatives of the nucleic acid aptamer include nucleotide-substituted RNA nucleic acid aptamers, skeleton-modified derivatives, peptide nucleic acid derivatives and derivatives of nucleic acid aptamer conjugated with radioactive molecules. A method for screening the nucleic acid aptamer comprises the following steps: firstly preparing HCV E1E2 proteins with histidine tags and then preparing pET200 / D / LacZ proteins with histidine tags, then immobilizing the proteins and designing a random nucleic acid library, and finally screening nucleic acid aptamers. Specifically, the screening step comprises the following steps: pre-treating the DNA library, performing reverse screening, performing forward screening, and repeatedly screening, to obtain the nucleic acid aptamer with strong competitiveness and optimized sequence length. The nucleic acid aptamer and derivatives thereof can be applied to preparing HCV E1E2 protein detection kits or diagnostic kits as well as agents for suppressing HCV infection in liver cells.
Owner:HUNAN UNIV

Expression carrier for black porgy antibiotic peptide Hepcidin and expression product and constructing preparation method

The invention discloses an expressing carrier of black porgy antibiotic peptide Hepcidin, expressing product and preparing method, which is characterized by the following: incorporating E. coliTrc promoter, protein project improving CKS gene and procaryotic expressing carrier pTrc-CKS of histidine tag (His-Tag); connecting to black porgy Hepcidin gene; constructing pTrc-CKS / hepcidin expressing plasmid; possessing P3C enzyme cutting site; fusing six histidine on C end; getting CKS-hepcidin; purifying through C end His-Tag affinity chromatography; getting the purified product; cutting CKS with P3C enzyme in fuse protein; getting the purified Hepcidin.
Owner:XIAMEN UNIV

Method for preparation of GLP-1 polypeptide or analogue thereof through MFH fusion protein and application of GLP-1 polypeptide or analogue thereof

ActiveCN104098702AAvoid insolubleAvoid the disadvantages of multiple impuritiesPeptide/protein ingredientsMetabolism disorderEscherichia coliStructural formula
The invention discloses a method for preparation of GLP-1 polypeptide or an analogue thereof through MFH fusion protein and application of the GLP-1 polypeptide or the analogue thereof, and belongs to the field of biotechnology. The structural formula of the MFH fusion protein of the GLP-1 polypeptide or the analogue thereof is MFH-DP-H6-E7-PEP, wherein the MFH is a protein fusion vector, DP is a formic acid hydrolysis site, H6 is a histidine label, E7 is a special protease cutting site and PEP is the GLP-1 polypeptide or the analogue thereof. The DNA of the code DP-H6-E7-PEP is connected to pMFH plasmid to obtain pMFH-PEP plasmid and then the pMFH-PEP plasmid is transferred into escherichia coli, MFH-DP-H6-E7-PEP fusion protein is obtained through prokaryotic expression, and formic acid hydrolysis, special protease hydrolysis and affinity chromatography are performed, so that GLP-1 polypeptide or the analogue thereof is obtained. According to the invention, the purposes of large-scale efficient expression of polypeptide, less steps of a peptide release process, mild condition and low production cost are achieved, and the GLP-1 polypeptide or the analogue thereof is suitable for industrial production.
Owner:HUBEI UNIV OF TECH

Novel preparation technology of targeting antitumor fusion protein LPO (lipid peroxidation)

The invention discloses a novel preparation technology of targeting antitumor fusion protein (lipid peroxidation). The novel preparation method comprises the steps of building a fusion expression protein which takes the glutathione S-transferase A (TrxA)-His-tag (His6-Tag)-SUMO protease recognition substrate as a protein soluble expression auxiliary fragment and takes LHRH (luteinizing hormone releasing hormone)-PEA (phenylethylamine) trans-cell penetrating peptides-ONC (LPO for short) as a target segment, connecting the two proteins with each other by a correct read frame and carrier positive sequence and converting to enter into expression bacteria, finally building fusion protein which is connected with six expression substances in series, crudely extracting, carrying out metal chelating medium purification in the presence of imidazole, and carrying out SUMO protease digestion. Compared with the LPO prepared by a conventional method, the LPO prepared by the novel preparation technology disclosed by the invention can obviously improve the inhibiting effect on the tumor cell lines such as colon cancer HT-29 cells, ovarian cancer OVCAR3 cells, cervical adenocarcinoma HeLa cells and liver cancer HepG-2 cells.
Owner:MILITARY VETERINARY RES INST PLA MILITARY MEDICAL ACAD OF SCI

Composite magnetic nanoparticles Fe3O4/MPS/PAA/NTA-Ni<2+> and preparation method and application thereof in separation and purification of histidine-tagged proteins

The invention relates to composite magnetic nanoparticles Fe3O4/MPS/PAA/NTA-Ni<2+> and a preparation method and an application thereof in separation and purification of histidine-tagged proteins, and belongs to the technical fields of nano magnetic materials and biological analysis. Fe3O4 magnetic nanoparticles with an average hydration particle size of 100-400 nm are used as a core, MPS surface modification is adopted for making the surface rich in double bonds, polycarboxyl-structure magnetic nanoparticles with an average hydration particle size of 100-600 nm are obtained through PAA coating, and then furthermore, the polycarboxyl-structure magnetic nanoparticles are coupled with NTA-Ni<2+> to obtain the composite magnetic nanoparticles Fe3O4/MPS/PAA/NTA-Ni<2+> having fast magnetic field response. The prepared composite magnetic nanoparticles enable the thickness of a coating layer to be controlled in nanometer scale; the prepared composite magnetic nanoparticles have the advantages of uniform size distribution, strong magnetic and low cost, have higher ability of enrichment and separation purification of the histidine-tagged proteins, and have the purification efficiency of the histidine-tagged proteins as high as 40-70 [mu]g/mg composite magnetic nanoparticles; and the composite magnetic nanoparticles can be repeatedly used.
Owner:HUBEI UNIV OF TECH
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products